China-based Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482) has entered into a partnership with Indonesia’s state-owned pharmaceutical company, Kimia Farma (KAEF), in the in vitro diagnostics (IVD) field. The collaboration aims to strengthen the healthcare infrastructure in Indonesia, although no financial details have been disclosed.
Background on Kimia Farma and Funding
Kimia Farma, the first pharmaceutical company in Indonesia, is funded by the Silk Road Fund, a medium and long-term development institution specifically for China’s Belt and Road Initiative, and the Indonesia Investment Authority (INA). This partnership highlights the growing collaboration between Chinese and Indonesian companies in the healthcare sector.
Wondfo’s Commitment to Indonesian Healthcare
Wondfo has been actively empowering the healthcare infrastructure in Indonesia since 2011. In 2019, the company collaborated with Merch on the diagnosis and treatment of thyroid diseases in remote areas of the country. Most recently, Wondfo and Merch initiated a national thyroid screening project in conjunction with the local physician association and the Indonesian Ministry of Health.-Fineline Info & Tech
